


Computational Methods for Next Generation Healthcare

Jianying Hu


IBM Fellow

Global Science Leader, AI for Healthcare
Director, Center for Computational Health

Computational Health: From Data to Impact



Patient Similarity Analytics for Precision Cohort



Goal

- Identify patients who are similar to a given patient of interest in a clinically meaningful way
- Identify a measure of clinical similarity between patients


Approach

- Supervised metric learning


Challenges Addressed

- Patient similarity is context dependent
- Feature dimensionality can be very large

Personalized Predictive Models - T2D Onset Prediction Example




- Insights for personalized intervention planning
- ✓ Diabetes patient population is heterogeneous
 - ✓ Traditional predictive modeling approaches only provide “universal” risk factor identification and ranking
 - ✓ Personalized predictive modeling approach provides patient specific risk factors and ranking
 - ✓ Clusters of risk factors, and patient risk profiles




Temporal Pattern Extraction with Deep Learning from EMR

- Temporal patterns and interactions are important features in predictive modeling in healthcare
- Prior methods do not sufficiently address the challenge of extracting such features from longitudinal patient record matrices (EHR).
- We developed an end-to-end Deep Learning framework tailored to longitudinal health care data to learn the temporal pattern and exploit them for risk prediction



Disease Onset Prediction Results (AUC)

	CHF	COPD
Baseline (Random Forest)	0.7156	0.6624
Deep Learning (Slow-Fusion Convolutional Neural Network)	0.7675	0.7388



SDM 2016

Diabetic Kidney Disease Prediction

www.nature.com/scientificreports/

SCIENTIFIC REPORTS
nature research

OPEN Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning

Received: 25 April 2019
Accepted: 1 August 2019
Published online: 14 August 2019

Masaki Makino¹, Ryo Yoshimoto¹, Masaki Ono¹, Toshinari Itoko¹, Takayuki Katsuki², Akiro Koseki³, Michiharu Kudo⁴, Kyochi Haida⁵, Jun Kuroda⁶, Ryosuke Yanagisawa⁷, Etsuji Saitoh⁸, Kiyotaka Hoshina⁹, Yukio Yuzawa¹⁰ & Atsushi Suzuki¹⁰

Artificial intelligence (AI) is expected to support clinical judgement in medicine. We constructed a new prediction model for diabetic kidney disease (DKD) using AI, predicting the progression of DKD and hemodialysis data using data machine learning, based on the electronic medical records (EMR) of 64,559 diabetes patients. AI extracted raw features from the previous 6 months as the reference period and selected 24 factors to find time series patterns relating to 6-month DKD aggravation, using a convolutional neural network. AI constructed the predictive model with 3,073 features, including time series data using logistic regression analysis, and evaluated the performance of DKD prediction. Furthermore, the group with DKD aggravation had a significantly higher incidence of hemodialysis than the non-aggravation group, over 10 years ($P = .000$). The new predictive model by AI could predict the risk of DKD and may contribute to more effective and accurate intervention to reduce hemodialysis.

Today, type 2 diabetes mellitus (T2DM) is a worldwide burden afflicting developed and developing countries¹. Chronic hyperglycemia and the subsequent accumulation of advanced glycation end-products result in multiple complications, including macrovascular and microvascular diseases². Among them, diabetic kidney disease (DKD), such as albuminuria, is one of the most frequent complications of T2DM and is associated with other cardiovascular diseases³. Several clinical risk factors, such as hypertension, dyslipidemia, hypertension and smoking, are related to the progression of DKD. Microalbuminuria is known as a good predictor of further progression of diabetic nephropathy and cardiovascular diseases, and early detection for DKD is important to prevent the use of expensive medicine, which could induce remission of DKD with microalbuminuria^{4–6}. However, a more precise predictive model that can timely intervention in DKD to prevent its further progression in diabetes patients without apparent symptoms or signs.

Artificial intelligence (AI) is changing our modern life and medical field. AI includes deep learning, virtual reality, etc. The potential of AI includes robot surgery, medical diagnosis, and rehabilitation. The medical branch includes informatics, which is expected to assist physicians in their clinical diagnosis and treatment decisions. The recent progress of machine-learning, with big data analysis, is contributing greatly, especially in the field of medical informatics. In this study, we used AI to predict the progression of DKD using historical information about previous models of prognosis and/or progression of complications in life-style related diseases, such as T2DM^{7–14}.

In general, clinical studies are designed to elucidate specific clinical risk factors by arranging background data or conditions before intervention. On the other hand, we performed clinical medicine under non-arranged

¹Department of Endocrinology and Metabolism, Fujita Health University, Toyoyake, Aichi, Japan. ²IBM Research, New York, NY, USA. ³Business Strategy Department, Dai-ichi Life Insurance Company, Limited, Tokyo, Japan. ⁴IT Business Planning Department, Dai-ichi Life Insurance Company, Limited, Tokyo, Japan. ⁵Division of Medical Information Systems, Fujita Health University, Toyoyake, Aichi, Japan. ⁶Department of Rehabilitation Therapy, Fujita Health University, Toyoyake, Aichi, Japan. ⁷Department of Nephrology, Fujita Health University, Toyoyake, Aichi, Japan. ⁸Department of Neurology, Fujita Health University, Toyoyake, Aichi, Japan. Correspondence and requests for materials should be addressed to A.S. (email: asaitoh@fujita-hu.ac.jp).


SCIENTIFIC REPORTS | (2019) 9:17482 | https://doi.org/10.1038/s41598-019-48261-5

Features	AUC	Accuracy
Profile	0.562	0.548
Profile + ICD10	0.562	0.557
Profile + ICD10 + YJCode	0.613	0.594
Profile + ICD10 + Blood Tests (latest)	0.644	0.606
Profile + ICD10 + YJCode +Blood Tests (latest and longitudinal)	0.656	0.610
Profile + ICD10 + YJCode +Blood Tests (latest and longitudinal) +Urinary Tests (latest and longitudinal)	0.729	0.691
Profile + ICD10 + YJCode +Blood Tests (latest and longitudinal) +Urinary Tests (latest and longitudinal) +Current Disease + Disease History	0.743	0.701


Impact of data coverage on performance

Key Findings

- ✓ Additional data categories improve prediction accuracy
- ✓ The aggravation of urinary protein observation is strongly affected by its variance over past 180 days
- ✓ DKD aggravation group had significantly higher incidence rates of Hemodialysis and Cardiovascular diseases



Survival analysis for hemodialysis



Survival analysis for CVD




- Deep Learning to extract temporal features
- Logistic regression for DKD prediction

Comprehensive Risk Assessment – Multi-Task Sparse Learning


Goal

- Simultaneously predict multiple risks
- Explore and exploit risk associations
- Identify common and unique risk factors

Use Cases: elder care risk assessment, diabetes complications



Improved Prediction Accuracy





Identify Association Among Risks

Multi-Task Learning for Diabetes Complications Prediction

Goal : Predict **when** a patient will develop complications after the initial T2DM diagnosis

Approach : Multi-task Survival Analysis

- **RankSvx**: A novel data-driven time-to-event modeling method
 - Accurate prediction of event times, and
 - Ranking of the relative risks among patients
- **Multi-task RankSvx** to simultaneously model multiple complication risks
 - leverage association between different diabetes complications
- Applied to predictions of retinopathy, neuropathy, nephropathy, vascular diseases





RankSvx outperforms traditional survival models and regression model in CI and MAE


Disease Progression Modeling



- GOAL → Provide comprehensive view and deeper understanding of a disease in terms of characteristics of underlying disease stages, areas of manifestation and progression pathways
- METHOD → Multi-layer probabilistic modeling framework to incorporate data from diverse sources
- Initial work on COPD; Work ongoing on enhanced methodologies & application to other conditions, including Huntington's (CHDI), T1D (JDRF), PD (MJFF).



Huntington's Disease Progression Modeling



Probabilistic Disease Progression Modeling

- Incorporate heterogeneous features coming from multiple studies and assessments covering multiple aspects of HD
- Provide comprehensive view of disease states and the progression of HD through a multi-layer probabilistic disease progression model
- Better understanding of disease sub-types
- Identify factors that are associated with disease progression patterns



Clinical Decision Support



Clinical Trial Design

- ✓ Improved understanding of disease progression: population/patient
- ✓ Insights into HD clinical assessments and sensitivities
- ✓ Objective baseline
- ✓ Cohort selection – trial enrichment
- ✓ Optimizing trial design – trial simulator
- ✓ Biomarker discovery

Challenges in Understanding HD Progression


- Disease manifestation along multiple dimensions with complex patterns
- Heterogeneous progression pathways
- No clear definitions of disease states

Integrated Huntington's Disease Progression Model



- Trained on data integrated from four prospective observational studies of HD (~16k case, 3k control)
- Discovered 9 disease states, over span of ~4 decades (prodromal, transition, manifest)
- Highlights (compared to prior-art HD progression indices)
 - Capturing multi-faceted manifestation throughout disease progression
 - Finer characterization, particularly of early states
 - Characterization of complex patterns of progression in transition (critical) states
 - Individual patient: more nuanced view of state of progression

Population view of multiple aspects of disease progression of HD



Annual transition probabilities through successive phenotypes ranges from 5% - 30%

Annual

Stage	Prodromal		Transition			Manifest			
	State 1	2	3	4	5	6	7	8	9
Prodromal	1	0.93 0.057	0.0021						
	2		0.81	0.13 0.048	0.013 0.0059				
	3			0.68 0.72	0.12 0.1	0.041 0.15	0.005 0.022	0.0026 0.0075	
	4								
	5					0.63			
Transition	6					0.75 0.72	0.21 0.24	0.036 0.048	0.0051 0.27
	7								
	8								
	9								1

Table 2. State sequence of an example patient

Visit date (years)	State from IHDPM	Shoulson and Fahn Stage
0		Premanifest
1.1	2	Premanifest
2.1	2	Premanifest
3.5	2	Premanifest
4.2	2	Premanifest
5.7	2	Premanifest
6.6	3	Premanifest
7.5	3	Premanifest
8.9	3	HD1
10.3	4	HD1
11.4	4	HD1
11.8	4	HD1
13.6	5	HD1
14.7	6	HD2

Causal Inference for Time Varying Treatment Strategies


- Goal → To provide causal estimate of effect of time varying treatments using observational data
- Method → G-Computation + hierarchical Bayesian models (post-processing)
- Challenges addressed:
 - Time varying treatment decisions
 - Outcomes recorded at irregular intervals/varying treatment durations
 - Multiple related drugs and multiple related outcomes



The G-formula:

$$E[Y_t(g)] = \sum_{\{\bar{l}_t\}} E[Y_t | \bar{L}_t = \bar{l}_t, \bar{A}_t = g(\bar{l}_t)] \prod_{m=1:t} p(L_m = l_m | \bar{L}_{m-1} = \bar{l}_{m-1}, \bar{A}_{\{m-1\}} = g(\bar{l}_{m-1}))$$

model for outcome given the past models for confounders given the past




Modeling of Parkinson's Disease Progression



Challenges in Understanding PD Progression


Summary scores mask symptom patterns



Inconsistent trajectory patterns across patients, even when controlling for early clinical presentation

Probabilistic Disease Progression Modeling

- Incorporate many clinical measures of PD
- Use control cases to subtract away non-PD effects (e.g. aging)
- Use input-output HMM approach to train personalized Medication Aware progression models



Improve Patient Engagement in Care Management

Engaging patients in interventions that are most effective for patients like them

Objectives

- Help care managers prioritize patients who will be more receptive to care management interventions.
- Help care managers set behavior goals/interventions based on intervention effectiveness estimates.

Data

Care management records (structured + unstructured)

Method

Patient similarity, Causal inference,



Key Finding

- Behavior phenotype-based care planning strategies could yield more effective intervention recommendations for goal attainment compared to population level strategies.




AI Triage Engine

Decision support system for medical triage to guide individuals to the next step of care



Medical triage tool deployed by a telemedicine service provider in Switzerland





NLP Pipeline
(CNN, Bi-GRU,
Bi-LSTM)

Auto-creation of
ontology and
language
agnostic KG


EMNLP 2018, EMBS 2018,
AMIA 2020

Hyperlocal Case Prediction


Framework for hyperlocal predictions of COVID-19 cases using novel compartmental models with ML enhancements




County/State/Country level daily prediction of cases with uncertainty under current or what-if conditions



Compartmental model (SEAIR) accounting for asymptomatic transmission, NPI and testing




Community risk model for Return To Work Advisor



Vaccine trial site identification



Resource Demand Prediction



Detection of Non-Pharmaceutical Interventions

Health Security 2019,
MedRxiv 2020, KDD
epiDAMIK 2020

Thank You !

